National Account Director, Payer (United/Optum/Emisar) jobs in United States
cer-icon
Apply on Employer Site
company-logo

Revolution Medicines · 4 days ago

National Account Director, Payer (United/Optum/Emisar)

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies. The National Account Director will establish and maintain strategic relationships with national payers to secure optimal market access for oncology medicines, leading engagement and developing account plans to support patient access.

Health CareLife ScienceMedical

Responsibilities

Translates national, brand-level payer strategy to key accounts across National Payers/PBMs, Regional Payers/PBMs/IDNs, VA/DoD, and state Medicaid plans, and work with Market Access leadership to refine value story and messaging as needed
Leads and oversees account activities such as driving rapid payer coverage and payer clinical pathways inclusion post launch in close collaboration with Medical Affairs
Leads cross-functional team across Commercial Field to pro-actively identify and resolve payer policy and pathway issues
Negotiates with customers to enable favorable formulary positioning and net revenue profitability
Creates medium to long term strategic payer/PBM/pathway engagement plan spanning multiple product and indication launches, and focuses on engaging beyond traditional rebates with tactics such as facilitating executive exchanges
Champions voice of customer to internal stakeholders and Commercial leadership

Qualification

Account managementPharmacy benefit managementNegotiation skillsOncology knowledgeStrategic partnershipsDesire to learnCommunication skillsTeam collaborationLeadership experience

Required

Bachelor's degree
Strong existing relationships with the UHC/Optum/Emisar organization and 10+ years in account management
Deep understanding of pharmacy benefit management, economic flows, and oral oncolytic trends within Medicare Part D, Commercial, Medicaid FFS and Managed Medicaid plans
Strong communication skills to educate and influence other Commercial stakeholders, including the executive leadership team, Access Marketing, and Strategic Pricing
Ability to clearly and efficiently communicate the value proposition of novel oncology therapies to customers
Excellent negotiation skills and pride in P&L and enterprise stewardship
Prior experience with pipeline products and product launches
Ability to partner effectively with Medical Affairs, Sales, and FRM teams
~30-50% travel required to customer meetings, industry conferences, and RevMed's home office in Redwood City, CA

Preferred

Advanced degree (MBA, Master's, PharmD, PhD)
Existing relationships with key regional plans that are OptumRx clients
Comprehensive understanding of federal accounts and VA/DoD processes and procedures
Experience in GI oncology, PDAC and/or NSCLC, including oral targeted therapies
Successful coordination of leadership exchanges and strategic partnerships beyond traditional contracting and rebate agreements
Desire to continuously learn, develop, and stay abreast of the evolving healthcare landscape
Passion for establishing high-functioning, collaborative relationships with new and rapidly growing teams
Prior experience or demonstrated development interest in payer marketing
Prior people leadership experience and ability to build team as company grows

Benefits

Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities

Company

Revolution Medicines

twittertwitter
company-logo
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Funding

Current Stage
Public Company
Total Funding
$2.25B
Key Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M

Leadership Team

leader-logo
Luan Wilfong
Chief Human Resources Officer
linkedin
leader-logo
Steve Kelsey
President
linkedin
Company data provided by crunchbase